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Background: To our knowledge no data exists comparing new generation commercially
available devices for transfemoral (TF) transcatheter aortic valve implantation (TAVI).
Methods: All consecutive patients from our single-center prospective registry with AS
treated with TAVI with from Edwards SAPIEN XT™ (SXT) vs. Medtronic CoreValve®
with AccuTrak™ delivery sy stem (MCVAT) when the devices became commercially
available were included. The study endpoints were according to the Valve Academic
Research Consortium (VARC) definitions.
Results: In total, 235 patients treated in our center by TF TAVI for severe AS were
included: 142 (60.4%) underwent SXT vs. 93 (39.6%) MCVAT. More females (60.6%
vs. 43.0%; p0.008) and smaller annulus size (23.21.9 vs. 24.32.0; p0.001) were
present in the SXT group. There were no differences between valves in 30-day combined
safety endpoint (SXT 26.1% vs. MCVAT 29.7%; p0.558), all-cause mortality (3.1% vs.
6.5%; p0.218), cardiovascular mortality (2.3% vs. 5.4%; p0.214), myocardial infarc-
tion (1.4% vs. 2.2%; p0.683) or stroke (0.7% vs. 1.1%; p0.774). Additionally, no
differences were observed in life-threatening bleeding (12.4% vs. 20.4%; p0.100) or
major vascular complications (12.0% vs. 9.7%; p0.583). Conversely, with SXT there
was a lower occurrence of conduction disturbances/arrhythmia (16.5% vs. 36.6%;
p0.001) and pacemaker implantation (5.8% vs. 33.3%; p0.001). Of note, a higher
device success (96.5% vs. 88.2%; p0.013) was observed with SXT. At median
follow-up of 328 (IQR 83-401) days, there was no difference in combined efficacy
endpoint (14.8% vs. 9.8%; p0.265) or mortality (8.0% vs. 6.5%; p0.654).
Conclusions: In our single center experience, there was a lower incidence of arrhythmia
and pacemaker, with higher device success with SXT. Differences in the characteristics of
the patients treated with each valve may explain some of these findings.
TCT-844
Clinical Outcome Of Patients With Low-Flow, Low-Gradient Aortic Stenosis
After Transcatheter Aortic Valve Implantation
Jury Schewel1, Dimitry Schewel1, Christian Frerker1, Thomas Thielsen1,
Felix Meinke1, Felix Kreidel1, Karl-Heinz Kuck1, Ulrich Schäfer1
1Asklepios Klinik St. Georg - University of Hamburg, Hamburg, Germany
Background: Previous studies showed that patients with impaired left ventricular (LV)
function and low-flow, low-gradient (LFLG) aortic stenosis (AS) are associated with high
operative risk and poor long-term outcome after surgical aortic valve replacement. The
aim of this study was to investigate the clinical outcome of LFLG AS after transcatheter
aortic valve implantation (TAVI).
Methods: 450 consecutive patients in high operative risk underwent TAVI with the
Medtronic Corevalve (Medtronic, Minneapolis, MN, USA) or Edwards Sapien (Edwards
Lifesience, Irvine, CA, USA) prostheses at our institution between June 2008 and
February 2012. Full data of 341 patients was collected. Of these, 190 patients presented
with normal-flow, high gradient (NFHG) AS (aortic surface area (ASA) 1.0 cm2, mean
gradient (Pmean)  30 mmHg, LV ejection fraction (LVEF)  50%) and 26 patients
with LFLG AS (ASA  1.0 cm2, Pmean  30 mmHg, LVEF  30%). Clinical
follow-up, echocardiography and measurements of NT-pro-BNP levels were analyzed at
10 days, 4 weeks, 6 month and 1 year after TAVI.
Results: Patients with LFLG AS had a higher all-cause mortality at 12 month after TAVI
compared to patients with NFHG AS (41% vs. 86%, p 0.0001). Nevertheless, surviving
patients with LFLG AS showed a significant and steady rise in LVEF after 4 weeks
(before 25.8  4.4% vs. 30 days 37.3  13.5%, p  0.05), after 6 month (39.1  12%)
and 1 year (51.7  4.6%) and a reduction of NT-pro-BNP (before 11956  8094 ng/L
vs. 12 month 1832  1261 ng/L, pn.s.). Furthermore, these patients showed reduced
symptoms of heart failure resulting in an improved NYHA functional class (LFLG vs.
NFHG: 4 weeks:1.1 0.8 vs.1.2 0.8; pn.s.; 6 month:1.4 0.5 vs.1.3
0.8; pn.s.; 12 month: 1.7  0.5 vs. 1.2  0.8; pn.s.).
Conclusions: This study shows that the all-cause mortality, 12 month after TAVI in
patients with LFLG AS is notably high. However, surviving patients presented an
enormous improvement in myocardial function and a high clinical benefit.
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Background: Previous studies showed that the paradoxical low-flow, low-gradient
(PLFLG) aortic stenosis (AS) is a highly challenging condition in terms of diagnostics and
therapy. Moreover, this subgroup demonstrates an increased all-cause mortality if treated
medically compared to surgically treated patients. The aim of this study was to investigate
the clinical outcome and mortality in patients with PLFLG AS after transcatheter aortic
valve implantation (TAVI).
Methods: 450 consecutive patients in high operative risk underwent TAVI with the
Medtronic Corevalve (Medtronic, Minneapolis, MN, USA) or Edwards Sapien (Edwards
Lifesience, Irvine, CA, USA) prostheses at our institution between June 2008 and
February 2012. Full data of 341 patients was collected. Of these, 190 patients presented
with normal-flow, high gradient (NFHG) AS (aortic surface area (ASA) 1.0 cm2, mean
gradient (Pmean) 30 mmHg, left ventricular ejection fraction (LVEF) 50%) and 28
patients with PLFLG AS (ASA 1.0 cm2, Pmean 30 mmHg, LVEF 50%, stroke
volume index (SVI)  35 ml/m2). Clinical follow-up, echocardiography and measure-
ments of NT-pro-BNP levels were analyzed at 10 days, 4 weeks, 6 month and 1 year after
TAVI.
Results: Patients with PLFLG AS had a similiar all-cause mortality at 12 month after
TAVI compared to patients with NFHG AS (85% vs. 85.6%, p0.771). The LVEF
decreased slightly but significant after 4 weeks (before 60.1  1.9% vs. 4 weeks 57.5 
5.5%, p0.049), but remained stable after 6 month (57.6  5.1%) and 1 year (56.9 
5.7%). Furthermore, patients with PLFLG AS showed slightly high values of NT-pro-
BNP at baseline but a similar reduction over time (PLFLG: before 3845 2966 ng/L vs.
1 year 2260 1814 ng/L, p0.079) in conjunction to reduced symptoms of heart failure.
NYHA functional capacity improved similar between both groups (PLFLG vs. NFHG:
4 weeks: 1  0.7 vs. 1.2  0.8; pn.s.; 6 month: 0.9  0.7 vs. 1.3  0.8;
pn.s.; 12 month: 1.3  1 vs. 1.2  0.8; pn.s.).
Conclusions: This study shows that patients with PLFLG AS have a similar benefit after
TAVI as patients with NFHG AS and should no longer be withheld from TAVI
procedures.
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Background: Transcatheter aortic valve implantation into failing aortic xenografts is
increasingly accepted as a new treatment option for patients in need of re-do open heart
surgery. Aim of the study was to compare the acute transvalvular hemodynamics between
the Medtronic Corevalve (MCV) prosthesis and the Edwards SAPIEN-valve (ESV) after
valve-in-valve implantation (ViVI).
Methods: A total of 24 pts (70.8% male, aged 72.66.7 years, mean logES
32.219.4%) underwent a transfemoral transcatheter ViVI for a failing aortic xenograft
at our institution. Due to the high frequency of small surgical valves (outer diameter - OD -
21mm: n11; 23mm n8; 25mm n2; 27mm n3) ViVI was predominantly done
with the MCV (17pts; 71%) compared to ESV (7pts; 29%: Edwards Sapien n2,
Sapien XT n5).
Results: Procedural success rate was 87.5%, with 1 pt. displaying moderate aortic
regurgitation (deep implanted MCV) and 2 pts. in need of a second MCV due to valve
embolisation into the ascending aorta (after attempting a high implantation within small
surgical xenografts, both with an OD of 21mm). Thirty-day-mortality was 0%. The
average mean aortic valve gradient (dPmean) decreased significantly after ViVI (30.614
vs. 14.36.1 mmHg). Acute hemodynamic data was significantly superior with MCV
implanted into xenografts with an OD 23mm (MCV n13: dPmean 12.03.9 mmHg;
ESV n3: dPmean 25.62.51 mmHg, p0.02) and severe patient prosthesis mismatch
was more likely with ESV (indexed effective orifice area: 0.640.19 vs. 0.860.16,
p0.04). The significantly higher gradient with ESV vs. MCV after ViVI into xenografts
with an OD of 23mm was confirmed by comparison of pooled and recently published
data of n64 ESV (Pmean 17.88.4 mmHg; p0.009).
Conclusions: The low 30d mortality suggests that percutaneous transcatheter ViV-
procedures for failing bioprosthetical aortic valves is an effective treatment option for
high-risk surgical patients. The MCV should be considered as the first choice in small
surgical xenografts (OD  23mm) due to lower remaining transvalvular gradients.
Nevertheless, the more demanding implantation with MCV indicates that a smaller
MCV-prosthesis (i.e. 23mm) is urgently needed to increase the safety of ViVI.
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Background: Scarcity of data is available regarding adequate choice of the postdilatation
balloon size in TAVI. Hereby, we demonstrate the value of CT scan to choose accurately
the post dilatation balloon size.
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